# HTL0039732 in Participants With Advanced Solid Tumours

> **NCT05944237** · PHASE1,PHASE2 · RECRUITING · sponsor: **Cancer Research UK** · enrollment: 150 (estimated)

## Conditions studied

- Neoplasms
- Prostatic Neoplasms, Castration-Resistant
- Stomach Neoplasms
- Esophageal Neoplasms
- Head and Neck Neoplasms
- Colorectal Neoplasms
- Pancreatic Neoplasms
- Lung Neoplasms
- Urinary Bladder Neoplasms
- Mesothelioma, Malignant
- Uterine Cervical Neoplasms
- Kidney Neoplasms
- Sarcoma
- Pheochromocytomas

## Interventions

- **DRUG:** HTL0039732 Capsules
- **DRUG:** HTL0039732 Capsules and atezolizumab infusion

## Key facts

- **NCT ID:** NCT05944237
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-13
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05944237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05944237, "HTL0039732 in Participants With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05944237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*